Inquire Before Buying
Speak to an Analyst 
Request Brochure 
Request CustomizationIMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.
Read More
Orphan Drugs Market Report by Drug Type (Biological, Non-Biological), Disease Type (Oncology, Hematology, Neurology, Cardiovascular, and Others), Phase (Phase I, Phase II, Phase III, Phase IV), Top Selling Drugs (Revlimid, Rituxan, Copaxone, Opdivo, Keytruda, Imbruvica, Avonex, Sensipar, Soliris, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Stores, and Others), and Region 2024-2032
Report Format: PDF+Excel | Report ID: SR112024A2382
Buy Now
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Orphan Drugs Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Drug Type
6.1 Biological
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Non-Biological
6.2.1 Market Trends
6.2.2 Market Forecast
7 Market Breakup by Disease Type
7.1 Oncology
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Hematology
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Neurology
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Cardiovascular
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Others
7.5.1 Market Trends
7.5.2 Market Forecast
8 Market Breakup by Phase
8.1 Phase I
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Phase II
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Phase III
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Phase IV
8.4.1 Market Trends
8.4.2 Market Forecast
9 Market Breakup by Top Selling Drugs
9.1 Revlimid
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Rituxan
9.2.1 Market Trends
9.2.2 Market Forecast
9.3 Copaxone
9.3.1 Market Trends
9.3.2 Market Forecast
9.4 Opdivo
9.4.1 Market Trends
9.4.2 Market Forecast
9.5 Keytruda
9.5.1 Market Trends
9.5.2 Market Forecast
9.6 Imbruvica
9.6.1 Market Trends
9.6.2 Market Forecast
9.7 Avonex
9.7.1 Market Trends
9.7.2 Market Forecast
9.8 Sensipar
9.8.1 Market Trends
9.8.2 Market Forecast
9.9 Soliris
9.9.1 Market Trends
9.9.2 Market Forecast
9.10 Others
9.10.1 Market Trends
9.10.2 Market Forecast
10 Market Breakup by Distribution Channel
10.1 Hospital Pharmacies
10.1.1 Market Trends
10.1.2 Market Forecast
10.2 Retail Pharmacies
10.2.1 Market Trends
10.2.2 Market Forecast
10.3 Online Stores
10.3.1 Market Trends
10.3.2 Market Forecast
10.4 Others
10.4.1 Market Trends
10.4.2 Market Forecast
11 Market Breakup by Region
11.1 North America
11.1.1 United States
11.1.1.1 Market Trends
11.1.1.2 Market Forecast
11.1.2 Canada
11.1.2.1 Market Trends
11.1.2.2 Market Forecast
11.2 Asia Pacific
11.2.1 China
11.2.1.1 Market Trends
11.2.1.2 Market Forecast
11.2.2 Japan
11.2.2.1 Market Trends
11.2.2.2 Market Forecast
11.2.3 India
11.2.3.1 Market Trends
11.2.3.2 Market Forecast
11.2.4 South Korea
11.2.4.1 Market Trends
11.2.4.2 Market Forecast
11.2.5 Australia
11.2.5.1 Market Trends
11.2.5.2 Market Forecast
11.2.6 Indonesia
11.2.6.1 Market Trends
11.2.6.2 Market Forecast
11.2.7 Others
11.2.7.1 Market Trends
11.2.7.2 Market Forecast
11.3 Europe
11.3.1 Germany
11.3.1.1 Market Trends
11.3.1.2 Market Forecast
11.3.2 France
11.3.2.1 Market Trends
11.3.2.2 Market Forecast
11.3.3 United Kingdom
11.3.3.1 Market Trends
11.3.3.2 Market Forecast
11.3.4 Italy
11.3.4.1 Market Trends
11.3.4.2 Market Forecast
11.3.5 Spain
11.3.5.1 Market Trends
11.3.5.2 Market Forecast
11.3.6 Russia
11.3.6.1 Market Trends
11.3.6.2 Market Forecast
11.3.7 Others
11.3.7.1 Market Trends
11.3.7.2 Market Forecast
11.4 Latin America
11.4.1 Brazil
11.4.1.1 Market Trends
11.4.1.2 Market Forecast
11.4.2 Mexico
11.4.2.1 Market Trends
11.4.2.2 Market Forecast
11.4.3 Others
11.4.3.1 Market Trends
11.4.3.2 Market Forecast
11.5 Middle East and Africa
11.5.1 Market Trends
11.5.2 Market Breakup by Country
11.5.3 Market Forecast
12 SWOT Analysis
12.1 Overview
12.2 Strengths
12.3 Weaknesses
12.4 Opportunities
12.5 Threats
13 Value Chain Analysis
14 Porters Five Forces Analysis
14.1 Overview
14.2 Bargaining Power of Buyers
14.3 Bargaining Power of Suppliers
14.4 Degree of Competition
14.5 Threat of New Entrants
14.6 Threat of Substitutes
15 Price Analysis
16 Competitive Landscape
16.1 Market Structure
16.2 Key Players
16.3 Profiles of Key Players
16.3.1 AbbVie Inc.
16.3.1.1 Company Overview
16.3.1.2 Product Portfolio
16.3.1.3 Financials
16.3.1.4 SWOT Analysis
16.3.2 Alexion Pharmaceuticals Inc.
16.3.2.1 Company Overview
16.3.2.2 Product Portfolio
16.3.2.3 Financials
16.3.2.4 SWOT Analysis
16.3.3 Amgen Inc.
16.3.3.1 Company Overview
16.3.3.2 Product Portfolio
16.3.3.3 Financials
16.3.3.4 SWOT Analysis
16.3.4 Biogen Inc.
16.3.4.1 Company Overview
16.3.4.2 Product Portfolio
16.3.4.3 Financials
16.3.4.4 SWOT Analysis
16.3.5 Bristol Myers Squibb Company
16.3.5.1 Company Overview
16.3.5.2 Product Portfolio
16.3.5.3 Financials
16.3.5.4 SWOT Analysis
16.3.6 F. Hoffmann-La Roche AG (Roche Holding AG)
16.3.6.1 Company Overview
16.3.6.2 Product Portfolio
16.3.6.3 SWOT Analysis
16.3.7 Jazz Pharmaceuticals Plc
16.3.7.1 Company Overview
16.3.7.2 Product Portfolio
16.3.7.3 Financials
16.3.7.4 SWOT Analysis
16.3.8 Johnson & Johnson
16.3.8.1 Company Overview
16.3.8.2 Product Portfolio
16.3.8.3 Financials
16.3.8.4 SWOT Analysis
16.3.9 Merck & Co. Inc.
16.3.9.1 Company Overview
16.3.9.2 Product Portfolio
16.3.9.3 Financials
16.3.9.4 SWOT Analysis
16.3.10 Novartis AG
16.3.10.1 Company Overview
16.3.10.2 Product Portfolio
16.3.10.3 Financials
16.3.10.4 SWOT Analysis
16.3.11 Pfizer Inc.
16.3.11.1 Company Overview
16.3.11.2 Product Portfolio
16.3.11.3 Financials
16.3.11.4 SWOT Analysis
16.3.12 Sanofi S.A.
16.3.12.1 Company Overview
16.3.12.2 Product Portfolio
16.3.12.3 Financials
16.3.12.4 SWOT Analysis
16.3.13 Takeda Pharmaceutical Company Limited
16.3.13.1 Company Overview
16.3.13.2 Product Portfolio
16.3.13.3 Financials
16.3.13.4 SWOT Analysis
16.3.14 Teva Pharmaceutical Industries Ltd
16.3.14.1 Company Overview
16.3.14.2 Product Portfolio
16.3.14.3 Financials
16.3.14.4 SWOT Analysis
List of Figures
Figure 1: Global: Orphan Drugs Market: Major Drivers and Challenges
Figure 2: Global: Orphan Drugs Market: Sales Value (in Billion US$), 2018-2023
Figure 3: Global: Orphan Drugs Market: Breakup by Drug Type (in %), 2023
Figure 4: Global: Orphan Drugs Market: Breakup by Disease Type (in %), 2023
Figure 5: Global: Orphan Drugs Market: Breakup by Phase (in %), 2023
Figure 6: Global: Orphan Drugs Market: Breakup by Top Selling Drugs (in %), 2023
Figure 7: Global: Orphan Drugs Market: Breakup by Distribution Channel (in %), 2023
Figure 8: Global: Orphan Drugs Market: Breakup by Region (in %), 2023
Figure 9: Global: Orphan Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
Figure 10: Global: Orphan Drugs (Biological) Market: Sales Value (in Million US$), 2018 & 2023
Figure 11: Global: Orphan Drugs (Biological) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 12: Global: Orphan Drugs (Non-Biological) Market: Sales Value (in Million US$), 2018 & 2023
Figure 13: Global: Orphan Drugs (Non-Biological) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 14: Global: Orphan Drugs (Oncology) Market: Sales Value (in Million US$), 2018 & 2023
Figure 15: Global: Orphan Drugs (Oncology) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 16: Global: Orphan Drugs (Hematology) Market: Sales Value (in Million US$), 2018 & 2023
Figure 17: Global: Orphan Drugs (Hematology) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 18: Global: Orphan Drugs (Neurology) Market: Sales Value (in Million US$), 2018 & 2023
Figure 19: Global: Orphan Drugs (Neurology) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 20: Global: Orphan Drugs (Cardiovascular) Market: Sales Value (in Million US$), 2018 & 2023
Figure 21: Global: Orphan Drugs (Cardiovascular) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 22: Global: Orphan Drugs (Other Disease Types) Market: Sales Value (in Million US$), 2018 & 2023
Figure 23: Global: Orphan Drugs (Other Disease Types) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 24: Global: Orphan Drugs (Phase I) Market: Sales Value (in Million US$), 2018 & 2023
Figure 25: Global: Orphan Drugs (Phase I) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 26: Global: Orphan Drugs (Phase II) Market: Sales Value (in Million US$), 2018 & 2023
Figure 27: Global: Orphan Drugs (Phase II) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 28: Global: Orphan Drugs (Phase III) Market: Sales Value (in Million US$), 2018 & 2023
Figure 29: Global: Orphan Drugs (Phase III) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 30: Global: Orphan Drugs (Phase IV) Market: Sales Value (in Million US$), 2018 & 2023
Figure 31: Global: Orphan Drugs (Phase IV) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 32: Global: Orphan Drugs (Revlimid) Market: Sales Value (in Million US$), 2018 & 2023
Figure 33: Global: Orphan Drugs (Revlimid) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 34: Global: Orphan Drugs (Rituxan) Market: Sales Value (in Million US$), 2018 & 2023
Figure 35: Global: Orphan Drugs (Rituxan) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 36: Global: Orphan Drugs (Copaxone) Market: Sales Value (in Million US$), 2018 & 2023
Figure 37: Global: Orphan Drugs (Copaxone) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 38: Global: Orphan Drugs (Opdivo) Market: Sales Value (in Million US$), 2018 & 2023
Figure 39: Global: Orphan Drugs (Opdivo) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 40: Global: Orphan Drugs (Keytruda) Market: Sales Value (in Million US$), 2018 & 2023
Figure 41: Global: Orphan Drugs (Keytruda) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 42: Global: Orphan Drugs (Imbruvica) Market: Sales Value (in Million US$), 2018 & 2023
Figure 43: Global: Orphan Drugs (Imbruvica) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 44: Global: Orphan Drugs (Avonex) Market: Sales Value (in Million US$), 2018 & 2023
Figure 45: Global: Orphan Drugs (Avonex) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 46: Global: Orphan Drugs (Sensipar) Market: Sales Value (in Million US$), 2018 & 2023
Figure 47: Global: Orphan Drugs (Sensipar) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 48: Global: Orphan Drugs (Soliris) Market: Sales Value (in Million US$), 2018 & 2023
Figure 49: Global: Orphan Drugs (Soliris) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 50: Global: Orphan Drugs (Other Drugs) Market: Sales Value (in Million US$), 2018 & 2023
Figure 51: Global: Orphan Drugs (Other Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 52: Global: Orphan Drugs (Hospital Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
Figure 53: Global: Orphan Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 54: Global: Orphan Drugs (Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
Figure 55: Global: Orphan Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 56: Global: Orphan Drugs (Online Stores) Market: Sales Value (in Million US$), 2018 & 2023
Figure 57: Global: Orphan Drugs (Online Stores) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 58: Global: Orphan Drugs (Other Distribution Channels) Market: Sales Value (in Million US$), 2018 & 2023
Figure 59: Global: Orphan Drugs (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 60: North America: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 61: North America: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 62: United States: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 63: United States: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 64: Canada: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 65: Canada: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 66: Asia Pacific: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 67: Asia Pacific: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 68: China: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 69: China: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 70: Japan: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 71: Japan: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 72: India: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 73: India: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 74: South Korea: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 75: South Korea: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 76: Australia: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 77: Australia: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 78: Indonesia: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 79: Indonesia: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 80: Others: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 81: Others: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 82: Europe: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 83: Europe: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 84: Germany: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 85: Germany: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 86: France: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 87: France: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 88: United Kingdom: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 89: United Kingdom: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 90: Italy: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 91: Italy: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 92: Spain: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 93: Spain: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 94: Russia: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 95: Russia: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 96: Others: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 97: Others: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 98: Latin America: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 99: Latin America: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 100: Brazil: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 101: Brazil: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 102: Mexico: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 103: Mexico: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 104: Others: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 105: Others: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 106: Middle East and Africa: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 107: Middle East and Africa: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 108: Global: Orphan Drugs Industry: SWOT Analysis
Figure 109: Global: Orphan Drugs Industry: Value Chain Analysis
Figure 110: Global: Orphan Drugs Industry: Porter’s Five Forces Analysis
List of Tables
Table 1: Global: Orphan Drugs Market: Key Industry Highlights, 2023 and 2032
Table 2: Global: Orphan Drugs Market Forecast: Breakup by Drug Type (in Million US$), 2024-2032
Table 3: Global: Orphan Drugs Market Forecast: Breakup by Disease Type (in Million US$), 2024-2032
Table 4: Global: Orphan Drugs Market Forecast: Breakup by Phase (in Million US$), 2024-2032
Table 5: Global: Orphan Drugs Market Forecast: Breakup by Top Selling Drugs (in Million US$), 2024-2032
Table 6: Global: Orphan Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
Table 7: Global: Orphan Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
Table 8: Global: Orphan Drugs Market Structure
Table 9: Global: Orphan Drugs Market: Key Players
Purchase options
Benefits of Customization
Personalize this research
Triangulate with your data
Get data as per your format and definition
Gain a deeper dive into a specific application, geography, customer, or competitor
Any level of personalization
Get in Touch With Us
UNITED STATES
Phone: +1-631-791-1145
INDIA
Phone: +91-120-433-0800
UNITED KINGDOM
Phone: +44-753-713-2163
Email: sales@imarcgroup.com
Client Testimonials
The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required
Read More
We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra
Read More
Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.
Read More.webp)
We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.
Read More
The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.
Read More
The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.
Read More
My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.
Read More
I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.
Read More.webp){kind=logo}
We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.
Read More
IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.
Read More